

Truncation

NEWS 38 AUG 18 Simultaneous left and right truncation added to ANABSTR

NEWS EXPRESS April 4 CURRENT WINDOWS VERSION IS V6.01a, CURRENT  
MACINTOSH VERSION IS V6.0b(ENG) AND V6.0Jb(JP),  
AND CURRENT DISCOVER FILE IS DATED 01 APRIL 2003  
NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 12:05:14 ON 11 SEP 2003

=> file .jacob

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY  
0.21

TOTAL  
SESSION  
0.21

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 12:05:23 ON 11 SEP 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 12:05:23 ON 11 SEP 2003

COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'MEDLINE' ENTERED AT 12:05:23 ON 11 SEP 2003

FILE 'EMBASE' ENTERED AT 12:05:23 ON 11 SEP 2003

COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 12:05:23 ON 11 SEP 2003

CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> (microdevice or microchip or microtiter)(P)photo?(P)pattern(P)substrate(P)binding

L1 1 FILE CAPLUS  
L2 2 FILE BIOSIS  
L3 1 FILE MEDLINE  
L4 1 FILE EMBASE  
L5 8 FILE USPATFULL

TOTAL FOR ALL FILES

L6 13 (MICRODEVICE OR MICROCHIP OR MICROTITER)(P) PHOTO?(P) PATTERN(P)  
SUBSTRATE(P) BINDING

=> dup rem

ENTER L# LIST OR (END):L6

PROCESSING COMPLETED FOR L6

L7 11 DUP REM L6 (2 DUPLICATES REMOVED)

=> d l7 ibib abs total

L7 ANSWER 1 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2003:237907 USPATFULL  
TITLE: Compositions and methods for the therapy and diagnosis  
of colon cancer  
INVENTOR(S): King, Gordon E., Shoreline, WA, UNITED STATES  
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES  
Xu, Jiangchun, Bellevue, WA, UNITED STATES  
Secrist, Heather, Seattle, WA, UNITED STATES  
Jiang, Yuqiu, Kent, WA, UNITED STATES  
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166064	A1	20030904
APPLICATION INFO.:	US 2002-99926	A1	20020314 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-33528, filed on 26 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-302051P	20010629 (60)
	US 2001-279763P	20010328 (60)
	US 2000-223283P	20000803 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	

NUMBER OF CLAIMS: 17  
EXEMPLARY CLAIM: 1  
LINE COUNT: 8531

AB Compositions and methods for the therapy and diagnosis of cancer,  
particularly colon cancer, are disclosed. Illustrative compositions  
comprise one or more colon tumor polypeptides, immunogenic portions  
thereof, polynucleotides that encode such polypeptides, antigen  
presenting cell that expresses such polypeptides, and T cells that are  
specific for cells expressing such polypeptides. The disclosed  
compositions are useful, for example, in the diagnosis, prevention  
and/or treatment of diseases, particularly colon cancer.

L7 ANSWER 2 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2003:106233 USPATFULL  
TITLE: Compositions and methods for the therapy and diagnosis  
of pancreatic cancer  
INVENTOR(S): Benson, Darin R., Seattle, WA, UNITED STATES  
Kalos, Michael D., Seattle, WA, UNITED STATES  
Lodes, Michael J., Seattle, WA, UNITED STATES  
Persing, David H., Redmond, WA, UNITED STATES  
Hepler, William T., Seattle, WA, UNITED STATES  
Jiang, Yuqiu, Kent, WA, UNITED STATES  
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104  
(U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003073144	A1	20030417
APPLICATION INFO.:	US 2002-60036	A1	20020130 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-333626P	20011127 (60)
	US 2001-305484P	20010712 (60)

US 2001-265305P	20010130 (60)
US 2001-267568P	20010209 (60)
US 2001-313999P	20010820 (60)
US 2001-291631P	20010516 (60)
US 2001-287112P	20010428 (60)
US 2001-278651P	20010321 (60)
US 2001-265682P	20010131 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092  
 NUMBER OF CLAIMS: 17  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 14253

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly pancreatic cancer, are disclosed. Illustrative compositions comprise one or more pancreatic tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly pancreatic cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2002:272801 USPATFULL  
 TITLE: Compositions and methods for the therapy and diagnosis of colon cancer  
 INVENTOR(S): Stolk, John A., Bothell, WA, UNITED STATES  
 Xu, Jiangchun, Bellevue, WA, UNITED STATES  
 Chenault, Ruth A., Seattle, WA, UNITED STATES  
 Meagher, Madeleine Joy, Seattle, WA, UNITED STATES  
 PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002150922	A1	20021017
APPLICATION INFO.:	US 2001-998598	A1	20011116 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-304037P	20010710 (60)
	US 2001-279670P	20010328 (60)
	US 2001-267011P	20010206 (60)
	US 2000-252222P	20001120 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092  
 NUMBER OF CLAIMS: 17  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 9233

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2002:251115 USPATFULL  
TITLE: Microdevice containing photorecognizable coding patterns and methods of using and producing the same thereof  
INVENTOR(S): Wu, Lei, San Diego, CA, UNITED STATES  
Wang, Xiaobo, San Diego, CA, UNITED STATES  
Tao, Gouliang, San Diego, CA, UNITED STATES  
Xu, Junquan, San Diego, CA, UNITED STATES  
Cheng, Jing, Beijing, CHINA  
Huang, Mingxiang, San Diego, CA, UNITED STATES  
Sun, Baoquan, Shangdong, CHINA  
Shao, Wei, Nanjing, CHINA  
Liu, Litian, Beijing, CHINA  
Chen, Depu, Beijing, CHINA  
Rothwarf, David M., La Jolla, CA, UNITED STATES  
Yang, Weiping, San Diego, CA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002137059	A1	20020926
APPLICATION INFO.:	US 2001-924428	A1	20010807 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	CN 2001-104318	20010228
	US 2001-264458P	20010126 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	MORRISON & FOERSTER LLP, 3811 VALLEY CENTRE DRIVE, SUITE 500, SAN DIEGO, CA, 92130-2332	
NUMBER OF CLAIMS:	114	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	3746	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention relates generally to the field of moiety or molecule analysis, isolation, detection and manipulation and library synthesis. In particular, the invention provides a microdevice, which microdevice comprises: a) a substrate; and b) a photorecognizable coding pattern on said substrate. Preferably, the microdevice does not comprise an anodized metal surface layer. Methods and kits for isolating, detecting and manipulating moieties, and synthesizing libraries using the microdevices are also provided. The invention further provides two-dimensional optical encoders and uses thereof.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2002:243051 USPATFULL  
TITLE: Compositions and methods for the therapy and diagnosis of ovarian cancer  
INVENTOR(S): Algate, Paul A., Issaquah, WA, UNITED STATES  
Jones, Robert, Seattle, WA, UNITED STATES  
Harlocker, Susan L., Seattle, WA, UNITED STATES  
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002132237	A1	20020919

APPLICATION INFO.: US 2001-867701 A1 20010529 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-207484P	20000526 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	25718	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 6 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2002:242791 USPATFULL

TITLE: Compositions and methods for the therapy and diagnosis of colon cancer

INVENTOR(S): King, Gordon E., Shoreline, WA, UNITED STATES  
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES  
Xu, Jiangchun, Bellevue, WA, UNITED STATES  
Secrist, Heather, Seattle, WA, UNITED STATES

PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002131971	A1	20020919
APPLICATION INFO.:	US 2001-33528	A1	20011226 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-302051P	20010629 (60)
	US 2001-279763P	20010328 (60)
	US 2000-223283P	20000803 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	8083	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 7 OF 11 USPATFULL on STN

ACCESSION NUMBER: 2002:235434 USPATFULL  
TITLE: Biosensors, reagents and diagnostic applications of directed evolution  
INVENTOR(S): Minshull, Jeremy, Menlo Park, CA, UNITED STATES  
Davis, S. Christopher, San Francisco, CA, UNITED STATES  
Welch, Mark, Fremont, CA, UNITED STATES  
Raillard, Sun Ai, Mountain View, CA, UNITED STATES  
Vogel, Kurt, Palo Alto, CA, UNITED STATES  
Krebber, Claus, Mountain View, CA, UNITED STATES  
PATENT ASSIGNEE(S): Maxygen, Inc., Redwood City, CA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002127623	A1	20020912
APPLICATION INFO.:	US 2001-920607	A1	20010731 (9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-222056P	20000731 (60)
	US 2000-244764P	20001031 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: LAW OFFICES OF JONATHAN ALAN QUINE, P O BOX 458, ALAMEDA, CA, 94501  
NUMBER OF CLAIMS: 130  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 7 Drawing Page(s)  
LINE COUNT: 6877

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Methods for sensing test stimuli using arrays of biopolymers are provided. Libraries of biopolymers, such nucleic acid variants, and expression products encoded by nucleic acid variants are provided. Reusable library arrays, and methods for their use are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 8 OF 11 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN

ACCESSION NUMBER: 2003:356878 BIOSIS  
DOCUMENT NUMBER: PREV200300356878  
TITLE: Improved Assay for the Collagen Binding Activity of von Willebrand Factor.  
AUTHOR(S): Germer, Matthias (1); Behrmann, Mathias (1); Kloft, Michael (1); Kotitschke, Ronald (1)  
CORPORATE SOURCE: (1) Research and Development, Biotest Pharma GmbH, Dreieich, Germany Germany  
SOURCE: Blood, (November 16 2002) Vol. 100, No. 11 , pp. Abstract No. 2744. print.  
Meeting Info.: 44th Annual Meeting of the American Society of Hematology Philadelphia, PA, USA December 06-10, 2002  
American Society of Hematology  
. ISSN: 0006-4971.  
DOCUMENT TYPE: Conference  
LANGUAGE: English

AB Background: Injury of the vessel wall leads to exposure of extracellular matrix and collagen fibers to the circulating blood. Platelets adhere to these structures and initiate arrest of blood flow. von Willebrand Factor (VWF) binds to collagen in the subendothelium and mediates adhesion via the GPIb/IX complex on the platelet. This biological activity can be examined directly in vitro using immobilised collagen on plates by means of an enzyme-linked immunosorbent assay. Although the first collagen-binding (VWF:CB) assay was described almost twenty years ago, this

test system has not yet found its way into routine analysis because the test results depend very much on the type and pre-treatment of collagen and the assay performance. Taking the proposed European Pharmacopoeia method as a starting point we established an optimised VWF:CB assay as an alternative method for the quantification of the activity in blood clotting factor VIII and VWF concentrates for the therapy of von Willebrand disease. Method: The assay is based on the following principle: 1. collagen fibrils (equine, type I) are immobilised on a **microtiter** plate, 2. serial dilutions of a reference preparation and VWF containing samples are prepared and bound to the precoated **microtiter** plate, 3. bound VWF is detected with a polyclonal antibody conjugate, 4. the TMB **substrate** reaction is followed **photometrically** with an ELISA reader. Results: VWF:CB test is highly specific and sensitive. Its broad working range for VWF (25 to 0,1 U/ml) under standard conditions is a prerequisite for its application for concentrates employing modern statistical procedures. Repeatability and intermediate precision are high (CV < 2 and 13 % respectively). Assay procedures for VWF antigen (VWF:Ag) and ristocetin co-factor activity (VWF:RCo) were analysed in parallel. For the VWF:Ag an immuno-turbidimetric method with a STA compact<sup>TM</sup> and STA Liatest<sup>TM</sup> VWF reagents was used. For VWF:RCo, platelet aggregation was followed by turbidimetry in an APACT 2<sup>TM</sup>. The latter is currently the standard method for the evaluation of the VWF activity in vitro although the test requires the non-physiological mediator ristocetin, is cumbersome and not always reproducible. The VWF:CB method appears not only to be easier to carry out than the vWF:RCo method but also to have a higher repeatability and intermediate precision and to allow better standardisation. Different commercial FVIII concentrates were tested for VWF:Ag, VWF:RCo and VWF:CB in parallel. The concentrates in this analysis gave different **patterns** of reactivity in these three test systems. Correlation between vWF:RCo and VWF:CB was excellent whereas the ratio of VWF:AG and VWF:CB depends on the type of product and may well serve as a measure for concentrate quality. Since collagen I fibrils are known to predominantly bind high VWF multimers this is likely to account for these differences. Discussion: The new VWF:CB assay is characterized by its wide range, safety, robustness, avoidance of a non-physiological activator and the option to determine the VWF:Ag simultaneously. Its high sensitivity may make it useful for the measurement of one functional activity of VWF in VWF concentrates and factor VIII products having VWF and for the clinical diagnosis of von Willebrand disease.

L7 ANSWER 9 OF 11 USPATFULL on STN

ACCESSION NUMBER: 97:83807 USPATFULL  
 TITLE: Use of specific properties of allergens, allergens from animal or botanical sources and methods for their isolation  
 INVENTOR(S): Berrens, Lubertus, Utrecht, Netherlands  
 PATENT ASSIGNEE(S): Laboratorios Leti S.A., Barcelona, Spain (non-U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 5667979		19970916
APPLICATION INFO.:	US 1990-461642		19900105 (7)

	NUMBER	DATE
PRIORITY INFORMATION:	EP 1989-200027	19890105
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	Granted	
PRIMARY EXAMINER:	Saunders, David	
LEGAL REPRESENTATIVE:	Young & Thompson	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	

NUMBER OF DRAWINGS: 14 Drawing Figure(s); 7 Drawing Page(s)

LINE COUNT: 1662

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB It was found that atopic allergens have enzymatic properties, in particular the properties to hydrolyze amide and/or ester linkages. These properties may be used for various purposes, e.g. for analysis of samples, standardization of pharmaceutical compositions and also for the preparation of the allergens in a pure form.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 1997:380130 CAPLUS

DOCUMENT NUMBER: 127:128632

TITLE: Light-directed assembly of nanoparticles

AUTHOR(S): Vossmeier, Tobias; DeIonno, Erica; Heath, James R.

CORPORATE SOURCE: Mol. Design. Inst., Lawrence Berkeley Lab. Dep. Chem. Biochem., Univ. California, Los Angeles, CA, 90095-1569, USA

SOURCE: Angewandte Chemie, International Edition in English (1997), 36(10), 1080-1083

CODEN: ACIEAY; ISSN: 0570-0833

PUBLISHER: Wiley-VCH

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Cleaned glass or silicon slides were treated with 3-aminopropyltrimethylethoxysilane and the surface amino groups were reacted with nitroveratryloxycarbonylglycine (NVOC) to produce **photosensitive** surface. Imagewise irradiation with  $\lambda > 340$  nm through a **microchip** mask yielded a **pattern** of free- and protected amino groups. The patterned **substrate** was kept overnight in the solution containing 12-aminododecane-capped Au particles to bind Au nanocrystals to the surface-bound amino-groups. To amplify particle **binding** the surface-bound Au particles were treated with 1,8-octanedithiol to yield free, surface-bound thiol groups on the areas where Au particles were attached to the surface. Following the dithiol treatment the slides were dipped again in the gold solution to bind more Au nanocrystals on the previously bound particles. This dithiol amplification was repeated several times to enhance the micropattern contrast until it was readily visible with the naked eye or via optical microscope.

L7 ANSWER 11 OF 11 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. on STN  
DUPLICATE 1

ACCESSION NUMBER: 1988:309885 BIOSIS

DOCUMENT NUMBER: BA86:26923

TITLE: SELECTIVE MODULATION OF TWO HUMAN MONOCYTE FC RECEPTORS FOR IGG BY IMMOBILIZED IMMUNE COMPLEXES.

AUTHOR(S): VAN DE WINKEL J G J; VAN DUIJNHOFEN H L P; VAN OMMEN R; CAPEL P J A; TAX W J M

CORPORATE SOURCE: DEP. EXP. IMMUNOL., STATE UNIV. UTRECHT, CATHARINESINGEL 59, 3511 GG UTRECHT, NETHERLANDS.

SOURCE: J IMMUNOL, (1988) 140 (10), 3515-3521.

CODEN: JOIMA3. ISSN: 0022-1767.

FILE SEGMENT: BA; OLD

LANGUAGE: English

AB Two types of IgG FcR, FcRI and FcRII, are constitutively expressed by human monocytes. FcRI (identified by mAb 32.2) binds human (h) IgG, FcRII (identified by mAb IV.3) has a low affinity for hIgG but interacts strongly with murine (m) IgG1. These receptors can be assayed by using indicator E sensitized by hIgG (EA-hIgG) or mIgG1 (EA-mIgG1), respectively. We further characterized these two FcR by modulation studies by using **substrate**-immobilized immune complexes containing rabbit IgG, goat IgG, or one of the mouse Ig classes or subclasses. After



incubating monocytes in **microtiter** wells containing such immune complexes, **binding** of the two types of indicator red cells on the apical surface of the monocytes was quantitated using a **photometric** assay employing the pseudoperoxidase activity of E. No effect on the **binding** of sensitized E was observed after incubation of monocytes with immune complexes containing mouse IgE, IgA, or IgM, or F(ab')<sub>2</sub> fragments of rabbit IgG. High concentrations of immune complexes containing IgG of mouse, rabbit, or goat, however, were able to induce a decrease in **binding** of both types of sensitized E, suggestive of modulation of both FcRI and FcRII. At lower concentrations of immune complexes, more selective **patterns** of modulation emerged. Under these conditions, immune complexes containing mIgG1 or mIgG2b, or, surprisingly, goat IgG induced a selective decrease in the **binding** of EA-mIgG1 (FcRII modulation), while immune complexes containing mIgG2a or rabbit IgG mainly affected the **binding** of EA-hIgG (FcRI modulation). By using anti-FcR mAb IV.3, it was confirmed that FcRII was modulated from the apical surface of monocytes after incubation on immune complex coated **substrates**. Selectivity of FcR-modulation was demonstrated by showing that under these conditions **binding** of anti-C receptor mAb, and several other anti-monocyte mAb did not decrease.

=> Jacob      CheuExaminerArt Unit 1641

L8            0 FILE CAPLUS  
L9            0 FILE BIOSIS  
L10           0 FILE MEDLINE  
L11           0 FILE EMBASE  
L12           0 FILE USPATFULL

TOTAL FOR ALL FILES

L13           0 JACOB CHEUEXAMINERART UNIT 1641

=>

=>

=>

=>

=>

=> file .chemistry  
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
48.84	49.05

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
-0.65	-0.65

CA SUBSCRIBER PRICE

FILE 'CAPLUS' ENTERED AT 12:11:52 ON 11 SEP 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOTECHNO' ENTERED AT 12:11:52 ON 11 SEP 2003  
COPYRIGHT (C) 2003 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'COMPENDEX' ENTERED AT 12:11:52 ON 11 SEP 2003  
Compendex Compilation and Indexing (C) 2003  
Elsevier Engineering Information Inc (EEI). All rights reserved.  
Compendex (R) is a registered Trademark of Elsevier Engineering Information Inc.

FILE 'ANABSTR' ENTERED AT 12:11:52 ON 11 SEP 2003  
COPYRIGHT (c) 2003 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'CERAB' ENTERED AT 12:11:52 ON 11 SEP 2003  
COPYRIGHT (C) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'METADEX' ENTERED AT 12:11:52 ON 11 SEP 2003  
COPYRIGHT (c) 2003 Cambridge Scientific Abstracts (CSA)

FILE 'USPATFULL' ENTERED AT 12:11:52 ON 11 SEP 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> (microchip or microdevice or microtiter) and substrate and binding partner

L14 6 FILE CAPLUS  
L15 0 FILE BIOTECHNO  
L16 0 FILE COMPENDEX  
L17 0 FILE ANABSTR  
L18 0 FILE CERAB  
L19 0 FILE METADEX  
L20 3543 FILE USPATFULL

TOTAL FOR ALL FILES

L21 3549 (MICROCHIP OR MICRODEVICE OR MICROTITER) AND SUBSTRATE AND BINDING PARTNER

=> l21 and (light or photo)

L22 1 FILE CAPLUS  
L23 0 FILE BIOTECHNO  
L24 0 FILE COMPENDEX  
L25 0 FILE ANABSTR  
L26 0 FILE CERAB  
L27 0 FILE METADEX  
L28 2956 FILE USPATFULL

TOTAL FOR ALL FILES

L29 2957 L21 AND (LIGHT OR PHOTO)

=> l29 and (bind(8A) (cell or DNA or protein or bacteria or virus))

L30 0 FILE CAPLUS  
L31 0 FILE BIOTECHNO  
L32 0 FILE COMPENDEX  
L33 0 FILE ANABSTR  
L34 0 FILE CERAB  
L35 0 FILE METADEX  
L36 2681 FILE USPATFULL

TOTAL FOR ALL FILES

L37 2681 L29 AND (BIND(8A) (CELL OR DNA OR PROTEIN OR BACTERIA OR VIRUS))

=> d l22 ibib abs total

L22 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2003 ACS on STN

ACCESSION NUMBER: 2003:396364 CAPLUS

DOCUMENT NUMBER: 138:381662

TITLE: Precipitation of metallic compound in method and apparatus for the identification and/or the quantification of a target compound obtained from a biological sample upon chips

INVENTOR(S): Remacle, Jose; Demarteau, Joseph

PATENT ASSIGNEE(S): Belg.

SOURCE: U.S. Pat. Appl. Publ., 27 pp., Cont.-in-part of U.S. Ser. No. 574,626.

CODEN: USXXCO

DOCUMENT TYPE: Patent  
LANGUAGE: English  
FAMILY ACC. NUM. COUNT: 3  
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2003096321	A1	20030522	US 2002-189288	20020701
EP 1054259	A1	20001122	EP 1999-870106	19990519
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 2003124522	A1	20030703	US 2000-574626	20000519
PRIORITY APPLN. INFO.:			EP 1999-870106	A 19990519
			EP 2000-870025	A 20000218
			US 2000-574626	A2 20000519

AB The present invention is related to a method for the identification and/or the quantification of a target compd. obtained from a sample, preferably a biol. sample, comprising the steps of putting into contact the target compd. with a capture mol. in order to allow a specific binding between said target compd. with a capture mol., said capture mol. being fixed upon a surface of a solid support according to an array comprising a d. of at least 20 discrete regions per cm<sup>2</sup>, each of said discrete regions being fixed with one species of capture mols., performing a reaction leading to a ppt. formed at the location of said binding, detg. the possible presence of ppt.(s) in discrete region(s), and correlating the presence of the ppt.(s) at the discrete region(s) with the identification and/or a quantification of said target compd. Silver enhancement was used in detection of DNA or proteins on biochips, in microarray anal. of gene expression of livers of phenobarbital-treated rats, and in detection of IgE and human autoimmune antibodies.

=> BIND(8A) (CELL OR DNA OR PROTEIN OR BACTERIA OR VIRUS)

L38 55410 FILE CAPLUS  
L39 31503 FILE BIOTECHNO  
L40 816 FILE COMPENDEX  
L41 140 FILE ANABSTR  
L42 0 FILE CERAB  
L43 14 FILE METADEX  
L44 45701 FILE USPATFULL

TOTAL FOR ALL FILES

L45 133584 BIND(8A) (CELL OR DNA OR PROTEIN OR BACTERIA OR VIRUS)

=> 145 and 128

L46 0 FILE CAPLUS  
L47 0 FILE BIOTECHNO  
L48 0 FILE COMPENDEX  
L49 0 FILE ANABSTR  
L50 0 FILE CERAB  
L51 0 FILE METADEX  
L52 2681 FILE USPATFULL

TOTAL FOR ALL FILES

L53 2681 L45 AND L28

=> 153 and py>1999

L54 0 FILE CAPLUS  
L55 0 FILE BIOTECHNO  
L56 0 FILE COMPENDEX  
L57 0 FILE ANABSTR  
L58 0 FILE CERAB  
L59 0 FILE METADEX  
L60 2374 FILE USPATFULL

TOTAL FOR ALL FILES  
L61 2374 L53 AND PY>1999

=> l61 and pattern

L62 0 FILE CAPLUS  
L63 0 FILE BIOTECHNO  
L64 0 FILE COMPENDEX  
L65 0 FILE ANABSTR  
L66 0 FILE CERAB  
L67 0 FILE METADEX  
L68 2017 FILE USPATFULL

TOTAL FOR ALL FILES  
L69 2017 L61 AND PATTERN

=> file .jacob

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	67.76	116.81

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-0.65	-1.30

FILE 'CAPLUS' ENTERED AT 12:19:38 ON 11 SEP 2003  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 12:19:38 ON 11 SEP 2003  
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC. (R)

FILE 'MEDLINE' ENTERED AT 12:19:38 ON 11 SEP 2003

FILE 'EMBASE' ENTERED AT 12:19:38 ON 11 SEP 2003  
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 12:19:38 ON 11 SEP 2003  
CA INDEXING COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

=> (microchip or microdevice or microtiter) (P) pattern(P) substrate(P) (DNA or virus or bacteria or cell or protein or RNA)

L70 15 FILE CAPLUS  
L71 10 FILE BIOSIS  
L72 5 FILE MEDLINE  
L73 7 FILE EMBASE  
L74 39 FILE USPATFULL

TOTAL FOR ALL FILES  
L75 76 (MICROCHIP OR MICRODEVICE OR MICROTITER) (P) PATTERN(P) SUBSTRATE (P) (DNA OR VIRUS OR BACTERIA OR CELL OR PROTEIN OR RNA)

=> l75 and py>1998

L76 9 FILE CAPLUS  
L77 6 FILE BIOSIS  
L78 2 FILE MEDLINE  
L79 3 FILE EMBASE  
L80 34 FILE USPATFULL

TOTAL FOR ALL FILES  
L81 54 L75 AND PY>1998

=> dup rem

PRIORITY INFORMATION: US 2001-277168P 20010320 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: LEXICON GENETICS INCORPORATED, 8800 TECHNOLOGY FOREST PLACE, THE WOODLANDS, TX, 77381-1160  
 NUMBER OF CLAIMS: 3  
 EXEMPLARY CLAIM: 1  
 LINE COUNT: 1074  
 AB Novel human polynucleotide and polypeptide sequences are disclosed that can be used in therapeutic, diagnostic, and pharmacogenomic applications.

L99 ANSWER 2 OF 23 USPATFULL on STN  
 ACCESSION NUMBER: 2003:237907 USPATFULL  
 TITLE: Compositions and methods for the therapy and diagnosis of colon cancer  
 INVENTOR(S): King, Gordon E., Shoreline, WA, UNITED STATES  
 Meagher, Madeleine Joy, Seattle, WA, UNITED STATES  
 Xu, Jiangchun, Bellevue, WA, UNITED STATES  
 Secrist, Heather, Seattle, WA, UNITED STATES  
 Jiang, Yuqiu, Kent, WA, UNITED STATES  
 PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003166064	A1	20030904
APPLICATION INFO.:	US 2002-99926	A1	20020314 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-33528, filed on 26 Dec 2001, PENDING Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul 2001, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-302051P	20010629 (60)
	US 2001-279763P	20010328 (60)
	US 2000-223283P	20000803 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	8531	
AB	Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.	

L99 ANSWER 3 OF 23 USPATFULL on STN  
 ACCESSION NUMBER: 2003:232512 USPATFULL  
 TITLE: Novel human transporter proteins  
 INVENTOR(S): Turner, Alex, The Woodlands, TX, UNITED STATES  
 Zambrowicz, Brian, The Woodlands, TX, UNITED STATES  
 Nehls, Michael, Stockdorf, GERMANY, FEDERAL REPUBLIC OF  
 Friedrich, Glenn A., The Woodlands, TX, UNITED STATES  
 Sands, Arthur T., The Woodlands, TX, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003162713	A1	20030828	<--
APPLICATION INFO.:	US 2003-368687	A1	20030214	(10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-556916, filed on 21 Apr 2000, GRANTED, Pat. No. US 6548271			

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-130552P	19990422 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Lance K. Ishimoto, LEXICON GENETICS INCORPORATED, 8800 Technology Forest Place, The Woodlands, TX, 77381	
NUMBER OF CLAIMS:	19	
EXEMPLARY CLAIM:	1	
LINE COUNT:	4251	

AB The present invention provides two novel families of novel human transporter proteins (NTPs). The invention additionally provides for agonists, antagonists, **antibodies**, antisense molecules that are specific for the NTPs, and further provides genetically engineered expression vectors for the NTPs and host comprising the same. The invention further provides for processes for identifying/producing molecules that effect NTP activity which comprise the use of the disclosed NTPs or genes encoding the same.

L99 ANSWER 4 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2003:207367 USPATFULL  
 TITLE: Microarray fabrication techniques and apparatus  
 INVENTOR(S): Chen, Shiping, Fremont, CA, UNITED STATES  
 Luo, Yuling, Castro Valley, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003143725	A1	20030731	<--
APPLICATION INFO.:	US 2003-351163	A1	20030123	(10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2001-791994, filed on 22 Feb 2001, PENDING			

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-183737P	20000222 (60)
	US 2000-188872P	20000313 (60)
	US 2000-216265P	20000706 (60)
	US 2000-220085P	20000721 (60)
	US 2000-244711P	20001030 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Charles D. Holland, Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA, 94304-1018	
NUMBER OF CLAIMS:	22	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	11 Drawing Page(s)	
LINE COUNT:	1821	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB Disclosed is a microarray printing system and methods of printing probe microarrays. The system has a print head formed of one or more bundles of individual capillaries, such as light-guiding capillaries. The bundles may especially be random bundles of capillaries that provide a large number of probes on the surface of a substrate. Methods of registering or correlating the distal and proximal ends of the capillaries are also provided. Further, the invention provides methods

and equipment for identifying defective microarrays that are missing one or more probes from the surface of the microarray.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L99 ANSWER 5 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2003:152948 USPATFULL  
TITLE: Micropatterning surfaces of polymeric substrates  
INVENTOR(S): Uhrich, Kathryn E., Plainfield, NJ, UNITED STATES  
Buettner, Helen M., West Windsor, NJ, UNITED STATES  
Schmalenberg, Kristine, Dunellen, NJ, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003104614	A1	20030605	<--
APPLICATION INFO.:	US 2002-215435	A1	20020809	(10)
RELATED APPLN. INFO.:	Continuation of Ser. No. WO 2001-US4842, filed on 12 Feb 2001, PENDING			

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-181763P	20000211 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A., P.O. BOX 2938, MINNEAPOLIS, MN, 55402	
NUMBER OF CLAIMS:	56	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	4 Drawing Page(s)	
LINE COUNT:	1201	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention is directed to an article which has a pattern of biologically active molecules stably adsorbed directly onto a polymeric substrate. The present invention also provides methods for preparing a pattern of biologically active molecules on the surface of a polymeric substrate, which include exposing a polymeric substrate to conditions that increase the polarity of a surface of the polymeric substrate, and contacting that surface with a stamp that includes a micron-sized pattern coated with biologically active molecules. The present invention also provides a method to spatially modulate the growth of a cell which includes contacting a cell with an article of the present invention for a time and under conditions sufficient to adhere the cell to the biologically active molecules and to grow the cell along the micron-sized pattern of biologically active molecules on the polymeric substrate.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L99 ANSWER 6 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2003:112837 USPATFULL  
TITLE: Methods and reagents for improved cell-based assays  
INVENTOR(S): Clausell, Adrian, San Diego, CA, UNITED STATES  
Gu, Jirong, Irvine, CA, UNITED STATES  
Reddy, Parameswara Meda, Brea, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003077569	A1	20030424	<--
APPLICATION INFO.:	US 2001-978498	A1	20011015	(9)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	BECKMAN COULTER INC, 4300 NORTH HARBOR BOULEVARD, P O BOX 3100, FULLERTON, CA, 928343100			
NUMBER OF CLAIMS:	95			

EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 11 Drawing Page(s)  
LINE COUNT: 2102

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The ability to efficiently determine the state of enzyme expression in cells has long been desired as material to the diagnosis of disease. This invention relates to cytoenzymology, and more particularly to improved reagents for use in cell-based assays, especially those using fluorogenic substrates.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L99 ANSWER 7 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2003:106233 USPATFULL  
TITLE: Compositions and methods for the therapy and diagnosis of pancreatic cancer  
INVENTOR(S): Benson, Darin R., Seattle, WA, UNITED STATES  
Kalos, Michael D., Seattle, WA, UNITED STATES  
Lodes, Michael J., Seattle, WA, UNITED STATES  
Persing, David H., Redmond, WA, UNITED STATES  
Hepler, William T., Seattle, WA, UNITED STATES  
Jiang, Yuqiu, Kent, WA, UNITED STATES  
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003073144	A1	20030417	<--
APPLICATION INFO.:	US 2002-60036	A1	20020130	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-333626P	20011127 (60)
	US 2001-305484P	20010712 (60)
	US 2001-265305P	20010130 (60)
	US 2001-267568P	20010209 (60)
	US 2001-313999P	20010820 (60)
	US 2001-291631P	20010516 (60)
	US 2001-287112P	20010428 (60)
	US 2001-278651P	20010321 (60)
	US 2001-265682P	20010131 (60)

DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092

NUMBER OF CLAIMS: 17  
EXEMPLARY CLAIM: 1  
LINE COUNT: 14253

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly pancreatic cancer, are disclosed. Illustrative compositions comprise one or more pancreatic tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly pancreatic cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L99 ANSWER 8 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2003:102248 USPATFULL  
TITLE: Nucleic acids encoding human transporter proteins  
INVENTOR(S): Turner, Alex, The Woodlands, TX, United States



PATENT ASSIGNEE(S): Zambrowicz, Brian, The Woodlands, TX, United States  
 Nehls, Michael, Stockdorf, GERMANY, FEDERAL REPUBLIC OF  
 Friedrich, Glenn A., The Woodlands, TX, United States  
 Sands, Arthur T., The Woodlands, TX, United States  
 Lexicon Genetics Incorporated, The Woodlands, TX,  
 United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6548271	B1	20030415	<--
APPLICATION INFO.:	US 2000-556916		20000421	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-130552P	19990422 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Myers, Carla J.	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1,2,3,8	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	4156	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention provides two novel families of novel human transporter proteins (NTPs). The invention additionally provides for agonists, antagonists, **antibodies**, antisense molecules that are specific for the NTPs, and further provides genetically engineered expression vectors for the NTPs and host comprising the same. The invention further provides for processes for identifying/producing molecules that effect NTP activity which comprise the use of the disclosed NTPs or genes encoding the same.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L99 ANSWER 9 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2003:99695 USPATFULL  
 TITLE: Use of streptococcus pneumoniae acyl carrier protein synthase crystal structure in diagnostics, antimicrobial drug design, and biosensors  
 INVENTOR(S): Chirgadze, Nicholas Yuri, Indianapolis, IN, UNITED STATES  
 Briggs, Stephen Lyle, Indianapolis, IN, UNITED STATES  
 Zhao, Genshi, Indianapolis, IN, UNITED STATES  
 McAllister, Kelly Ann, Indianapolis, IN, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003068802	A1	20030410	<--
APPLICATION INFO.:	US 2001-897645	A1	20010629	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-215577P	20000630 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	ELI LILLY AND COMPANY, PATENT DIVISION, P.O. BOX 6288, INDIANAPOLIS, IN, 46206-6288	
NUMBER OF CLAIMS:	31	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	9 Drawing Page(s)	
LINE COUNT:	14574	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Provided are methods of purifying and crystallizing Streptococcus pneumoniae acyl carrier protein synthase (AcpS) enzyme, crystals of

AcpS, the use of such crystals to determine the three-dimensional structure of AcpS enzymes, and the three-dimensional structure of AcpS. The three-dimensional crystal structure of AcpS can be used in medical diagnostics to produce **antibodies** that permit detection of *Streptococcus pneumoniae* both in vitro and in vivo. The three-dimensional crystal structure of AcpS can also be used in pharmaceutical discovery and development to identify and design compounds that inhibit the biochemical activity of AcpS enzyme in bacteria. Inhibitory compounds identified in this way can be optimized by structure/activity studies to develop antibacterial pharmaceutical compounds useful for the prevention or treatment of bacterial infections.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L99 ANSWER 10 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2003:57447 USPATFULL

TITLE: Apparatus and method for simultaneously conducting multiple chemical reactions

INVENTOR(S): Barth, Phillip W., Portola Valley, CA, UNITED STATES  
Amorese, Douglas A., Los Altos, CA, UNITED STATES  
Schembri, Carol T., San Mateo, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003040011	A1	20030227	<--
APPLICATION INFO.:	US 2001-938909	A1	20010824	(9)
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	AGILENT TECHNOLOGIES, INC., Legal Department, DL429, Intellectual Property Administration, P.O. Box 7599, Loveland, CO, 80537-0599			
NUMBER OF CLAIMS:	48			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	5 Drawing Page(s)			
LINE COUNT:	1624			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method and apparatus for simultaneously conducting multiple chemical reactions combine a test sample with a chemical reactant in a plurality of closed reaction chambers to produce reaction products. The method comprises assembling a plate having the test sample in a plurality of spatially arranged wells with a microarray of similarly spatially arranged surface bound chemical reactants to form the sealed apparatus having the plurality of closed reaction chambers. The apparatus is sealed such that it is gas, liquid and/or fluid tight. The seal may be accomplished with a flexible array substrate or a flexible gasket, and one or more of mechanical clamps, external fluid pressure, radiation, heat, vacuum and an adhesive. The sealed apparatus can be subjected to various reaction conditions, such as intense mechanical agitation and a controlled temperature environment. A kit comprises one or more of the elements of the apparatus.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L99 ANSWER 11 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2003:30423 USPATFULL

TITLE: Magnetic immobilization of cells

INVENTOR(S): Casagrande, Rocco, Newton, MA, UNITED STATES  
Wang, Evelyn, Haddonfield, NJ, UNITED STATES  
Kirk, Gregory, Winchester, MA, UNITED STATES  
Nussbaum, Michael, Newton, MA, UNITED STATES  
Kim, Enoch, Boston, MA, UNITED STATES  
Raphel, Aaron, Somerville, MA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003022370	A1	20030130	<--
APPLICATION INFO.:	US 2002-84063	A1	20020228	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-307843P	20010727 (60)
	US 2001-334593P	20011203 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KENYON & KENYON, 1500 K STREET, N.W., SUITE 700, WASHINGTON, DC, 20005	
NUMBER OF CLAIMS:	214	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	1990	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The present invention relates to an apparatus and methods that immobilize one or more cells associated with magnetic material on a substrate on which are located one or more magnetic receptacle(s). Alternatively, in another aspect the present invention, the device arrays cells associated with magnetic material on a substrate having a pattern of magnetic receptacles disposed thereon. The size of the magnetic receptacle(s) determines the number of target cells that it is capable of immobilizing. The size of the magnetic receptacle is defined by the strength of a localized magnetic field gradient. The localized magnetic field gradient maybe derived from 1) permanent magnets embedded in the substrate or alternatively, the localized magnetic field gradient may be derived from an 2) external magnet whose strength is focused by objects of highly-permeable-magnetic material which create localized magnetic field gradients. The invention apparatus comprises a removable cell delivery device and a substrate, which has one or more magnetic receptacles disposed thereon.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L99 ANSWER 12 OF 23 USPATFULL on STN  
 ACCESSION NUMBER: 2003:10636 USPATFULL  
 TITLE: Directed evolution biosensors  
 INVENTOR(S): Lerner, Michael R., Rancho Santa Fe, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2003008331	A1	20030109	<--
APPLICATION INFO.:	US 2002-229973	A1	20020828	(10)
RELATED APPLN. INFO.:	Division of Ser. No. US 2000-647653, filed on 4 Oct 2000, GRANTED, Pat. No. US 6475733 A 371 of International Ser. No. WO 1999-US7566, filed on 6 Apr 1999, PENDING			

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-80915P	19980406 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Konstantinos Andrikopoulos, Esq, Wolf, Greenfield & Sacks, P.C., 600 Atlantic Avenue, Boston, MA, 02210	
NUMBER OF CLAIMS:	14	
EXEMPLARY CLAIM:	1	
LINE COUNT:	868	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention exploits the evolutionary principles responsible for the development of the broad spectrum general odorant detector system, to

create a G-protein coupled receptor (GPCR) based system capable of detecting and discriminating between thousands of chemicals. The means is to subject a defined set of receptors such as G-protein coupled receptors, tyrosine kinase receptors, and/or ion channels, to the types of evolutionary forces that have created the array of approximately 1,000 natural receptors used in general olfaction by higher animals. This goal is accomplished by `directed evolution-in-a-test-tube` by imposing very high rates of mutation and extremely strict selection criteria to create a sensor. The novel sensor is selected using a sensitive melanophore-based functional bioassay. Stimulation of the sensor upon interaction with chemical signatures derived from ordinances will result in a calcium ion flux rapidly detectable as a fluorescent signal.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L99 ANSWER 13 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2002:308336 USPATFULL  
 TITLE: Methods for enhancing the efficacy of cancer therapy  
 INVENTOR(S): Pennica, Diane, Burlingame, CA, UNITED STATES  
 Polakis, Paul, Burlingame, CA, UNITED STATES  
 Szeto, Wayne, San Francisco, CA, UNITED STATES  
 Tice, David, San Mateo, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002173461	A1	20021121	<--
APPLICATION INFO.:	US 2001-901812	A1	20010710	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-228914P	20000829 (60)
	US 2000-175849P	20000113 (60)
	US 2000-197089P	20000414 (60)

DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: KNOBBE MARTENS OLSON & BEAR LLP, 620 NEWPORT CENTER DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660  
 NUMBER OF CLAIMS: 66  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 47 Drawing Page(s)  
 LINE COUNT: 4875  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.  
 AB The invention concerns the identification of tumor antigens the expression of which is selectively upregulated by retinoid treatment. The invention further concerns improved methods of cancer treatment and, in particular, methods enhancing the efficacy of the treatment of cancers characterized by aberrant Wnt signaling by administration of retinoic acid or other retinoids.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L99 ANSWER 14 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2002:290729 USPATFULL  
 TITLE: Cell surface receptors for the detection and identification of compounds  
 INVENTOR(S): Lerner, Michael R., Dallas, TX, United States  
 PATENT ASSIGNEE(S): Lerner Pharmaceuticals, Inc., Woodbridge, CT, United States (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6475733	B1	20021105	<--
	WO 9951777		19991014	<--

APPLICATION INFO.: US 2000-647653 20001004 (9)  
 WO 1999-US7566 19990406  
 20001204 PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 1998-80915P	19980406 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Horlick, Kenneth R.	
LEGAL REPRESENTATIVE:	Wolf, Greenfield & Sacks, P.C.	
NUMBER OF CLAIMS:	27	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	0 Drawing Figure(s); 0 Drawing Page(s)	
LINE COUNT:	959	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention exploits the evolutionary principles responsible for the development of the broad spectrum general odorant detector system, to create a cell-surface receptor based system capable of detecting and discriminating between thousands of chemicals. This is accomplished by subjecting a defined set of cell-surface receptors such as G-protein coupled receptors, tyrosine kinase receptors, and/or ion channels, to the types of evolutionary forces that have created the array of approximately 1,000 natural receptors used in general olfaction by higher animals. This goal is further accomplished by a `directed evolution-in-a-test-tube` method, imposing very high rates of mutation and extremely strict selection criteria to create a sensor. The novel sensor of the present invention is selected using a sensitive melanophore-based functional bioassay.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L99 ANSWER 15 OF 23 USPATFULL on STN  
 ACCESSION NUMBER: 2002:272801 USPATFULL  
 TITLE: Compositions and methods for the therapy and diagnosis of colon cancer  
 INVENTOR(S): Stolk, John A., Bothell, WA, UNITED STATES  
 Xu, Jiangchun, Bellevue, WA, UNITED STATES  
 Chenault, Ruth A., Seattle, WA, UNITED STATES  
 Meagher, Madeleine Joy, Seattle, WA, UNITED STATES  
 PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002150922	A1	20021017	<--
APPLICATION INFO.:	US 2001-998598	A1	20011116	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-304037P	20010710 (60)
	US 2001-279670P	20010328 (60)
	US 2001-267011P	20010206 (60)
	US 2000-252222P	20001120 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	9233	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions

comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L99 ANSWER 16 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2002:243051 USPATFULL  
TITLE: Compositions and methods for the therapy and diagnosis of ovarian cancer  
INVENTOR(S): Algate, Paul A., Issaquah, WA, UNITED STATES  
Jones, Robert, Seattle, WA, UNITED STATES  
Harlocker, Susan L., Seattle, WA, UNITED STATES  
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES, 98104 (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002132237	A1	20020919	<--
APPLICATION INFO.:	US 2001-867701	A1	20010529	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-207484P	20000526 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	11	
EXEMPLARY CLAIM:	1	
LINE COUNT:	25718	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L99 ANSWER 17 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2002:242791 USPATFULL  
TITLE: Compositions and methods for the therapy and diagnosis of colon cancer  
INVENTOR(S): King, Gordon E., Shoreline, WA, UNITED STATES  
Meagher, Madeleine Joy, Seattle, WA, UNITED STATES  
Xu, Jiangchun, Bellevue, WA, UNITED STATES  
Secrist, Heather, Seattle, WA, UNITED STATES  
PATENT ASSIGNEE(S): Corixa Corporation, Seattle, WA, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002131971	A1	20020919	<--
APPLICATION INFO.:	US 2001-33528	A1	20011226	(10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2001-920300, filed on 31 Jul 2001, PENDING			

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-302051P	20010629 (60)
	US 2001-279763P	20010328 (60)
	US 2000-223283P	20000803 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	SEED INTELLECTUAL PROPERTY LAW GROUP PLLC, 701 FIFTH AVE, SUITE 6300, SEATTLE, WA, 98104-7092	
NUMBER OF CLAIMS:	17	
EXEMPLARY CLAIM:	1	
LINE COUNT:	8083	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB Compositions and methods for the therapy and diagnosis of cancer, particularly colon cancer, are disclosed. Illustrative compositions comprise one or more colon tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly colon cancer.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L99 ANSWER 18 OF 23 USPATFULL on STN  
 ACCESSION NUMBER: 2002:235434 USPATFULL  
 TITLE: Biosensors, reagents and diagnostic applications of directed evolution  
 INVENTOR(S): Minshull, Jeremy, Menlo Park, CA, UNITED STATES  
 Davis, S. Christopher, San Francisco, CA, UNITED STATES  
 Welch, Mark, Fremont, CA, UNITED STATES  
 Raillard, Sun Ai, Mountain View, CA, UNITED STATES  
 Vogel, Kurt, Palo Alto, CA, UNITED STATES  
 Krebber, Claus, Mountain View, CA, UNITED STATES  
 PATENT ASSIGNEE(S): Maxygen, Inc., Redwood City, CA (U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002127623	A1	20020912	<--
APPLICATION INFO.:	US 2001-920607	A1	20010731	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-222056P	20000731 (60)
	US 2000-244764P	20001031 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LAW OFFICES OF JONATHAN ALAN QUINE, P O BOX 458, ALAMEDA, CA, 94501	
NUMBER OF CLAIMS:	130	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	7 Drawing Page(s)	
LINE COUNT:	6877	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

AB Methods for sensing test stimuli using arrays of biopolymers are provided. Libraries of biopolymers, such nucleic acid variants, and expression products encoded by nucleic acid variants are provided. Reusable library arrays, and methods for their use are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L99 ANSWER 19 OF 23 USPATFULL on STN  
 ACCESSION NUMBER: 2002:228458 USPATFULL  
 TITLE: Novel human kinase and polynucleotides encoding the

INVENTOR(S): same  
 Walke, D. Wade, Spring, TX, UNITED STATES  
 Miranda, Maricar, Houston, TX, UNITED STATES  
 Yu, Xuanchuan (Sean), Houston, TX, UNITED STATES  
 Friddle, Carl Johan, The Woodlands, TX, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002123621	A1	20020905	<--
APPLICATION INFO.:	US 2001-16985	A1	20011207	(10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-251941P	20001207 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	Lance K. Ishimoto, Lexicon Genetics Incorporated, 4000 Research Forest Drive, The Woodlands, TX, 77381	
NUMBER OF CLAIMS:	2	
EXEMPLARY CLAIM:	1	
LINE COUNT:	1067	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Novel human polynucleotide and polypeptide sequences are disclosed that can be used in therapeutic, diagnostic, and pharmacogenomic applications.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L99 ANSWER 20 OF 23 USPATFULL on STN  
 ACCESSION NUMBER: 2002:206113 USPATFULL  
 TITLE: Secreted factors  
 INVENTOR(S): Stanton, Lawrence W., Redwood City, CA, UNITED STATES  
 White, R. Tyler, Fremont, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002110804	A1	20020815	<--
APPLICATION INFO.:	US 2001-809545	A1	20010314	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-193548P	20000331 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	KNOBBE MARTENS OLSON & BEAR LLP, 620 NEWPORT CENTER DRIVE, SIXTEENTH FLOOR, NEWPORT BEACH, CA, 92660	
NUMBER OF CLAIMS:	26	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	59 Drawing Page(s)	
LINE COUNT:	5729	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention concerns new secreted factors encoded by clones P00184\_D11 (SEQ ID NO:1), P00185\_D11 (SEQ ID NO:3), P00188\_D12 (SEQ ID NO:5), P00188\_E01 (SEQ ID NO:7), P00194\_G01 (SEQ ID NO:9), P00194\_G05 (SEQ ID NO:11), P00194\_H10 (SEQ ID NO:13), P00199\_D08 (SEQ ID NO:15), P00203\_D04 (SEQ ID NO:17), P00203\_E06 (SEQ ID NO:19), P00209\_F06 (SEQ ID NO:21), P00219\_D02 (SEQ ID NO:23), P00219\_F06 (SEQ ID NO:25), P00220\_H05 (SEQ ID NO:27), P00222\_G03 (SEQ ID NO:29), P00225\_C01 (SEQ ID NO:32), P00227\_D11 (SEQ ID NO:34), P00228\_F03 (SEQ ID NO:36), P00233\_H08 (SEQ ID NO:38), P00235\_G08 (SEQ ID NO:40), P00239\_C11 (SEQ ID NO:42), P00240\_E05 (SEQ ID NO:45), P00247\_A04 (SEQ ID NO:50), P00248\_B04 (SEQ ID NO:52), P00249\_F09 (SEQ ID NO:54), P00258\_A10 (SEQ ID NO:56), P00262\_C10 (SEQ ID NO:58), P00269\_H08 (SEQ ID NO:62), P00628\_H02 (SEQ ID NO:66), P00629\_C08 (SEQ ID NO:68), P00641\_G11 (SEQ ID NO:71), P00648\_E12 (SEQ ID NO:73), P00697\_C03



(SEQ ID NO:75), and other mammalian homologues and variants of such factor, as well as polynucleotides encoding them. The invention further concerns methods and means for producing such factors and their use in the diagnosis and treatment of various cardiac, renal or inflammatory diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L99 ANSWER 21 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2002:181558 USPATFULL  
TITLE: Low volume chemical and biochemical reaction system  
INVENTOR(S): Jovanovich, Stevan B., Livermore, CA, United States  
Roach, David J., Los Gatos, CA, United States  
Hadd, Andrew G., San Jose, CA, United States  
Hellman, Bo E. R., Palo Alto, CA, United States  
PATENT ASSIGNEE(S): Molecular Dynamics, Inc., Sunnyvale, CA, United States  
(U.S. corporation)

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6423536	B1	20020723	<--
APPLICATION INFO.:	US 2000-577199		20000523	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 1999-146732P	19990802 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Beisner, William H.	
LEGAL REPRESENTATIVE:	Schneck, Thomas, Schneck, David M.	
NUMBER OF CLAIMS:	64	
EXEMPLARY CLAIM:	1,26,36,47	
NUMBER OF DRAWINGS:	33 Drawing Figure(s); 20 Drawing Page(s)	
LINE COUNT:	2260	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB A method and device for preparing nanoscale reactions. An automated system utilizes an array of reaction chambers. The ends of the chambers are temporarily sealed with deformable membranes and reactions effected by incubation or temperature cycling. Reaction mixtures may be assembled by using the reaction containers to meter reaction components. After the reaction is finished, the reaction containers may be dispensed onto a substrate and the reaction products analyzed. An automated transfer device may be used for automated transport of the reaction container array or other transportable elements.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L99 ANSWER 22 OF 23 USPATFULL on STN

ACCESSION NUMBER: 2002:99083 USPATFULL  
TITLE: Microarray fabrication techniques and apparatus  
INVENTOR(S): Chen, Shiping, Rockville, MD, UNITED STATES  
Luo, Yuling, Castro Valley, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2002051979	A1	20020502	<--
	US 6594432	B2	20030715	
APPLICATION INFO.:	US 2001-791994	A1	20010222	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-183737P	20000222 (60)
	US 2000-188872P	20000313 (60)
	US 2000-216265P	20000706 (60)

US 2000-220085P 20000721 (60)  
 US 2000-244711P 20001030 (60)  
 DOCUMENT TYPE: Utility  
 FILE SEGMENT: APPLICATION  
 LEGAL REPRESENTATIVE: Charles D. Holland, Morrison & Foerster LLP, 755 Page  
 Mill Road, Palo Alto, CA, 94304-1018  
 NUMBER OF CLAIMS: 22  
 EXEMPLARY CLAIM: 1  
 NUMBER OF DRAWINGS: 11 Drawing Page(s)  
 LINE COUNT: 1823  
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Disclosed is a microarray printing system and methods of printing probe  
 microarrays. The system has a print head formed of one or more bundles  
 of individual capillaries, such as light-guiding capillaries. The  
 bundles may especially be random bundles of capillaries that provide a  
 large number of probes on the surface of a substrate. Methods of  
 registering or correlating the distal and proximal ends of the  
 capillaries are also provided. Further, the invention provides methods  
 and equipment for identifying defective microarrays that are missing one  
 or more probes from the surface of the microarray.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L99 ANSWER 23 OF 23 USPATFULL on STN  
 ACCESSION NUMBER: 2001:188804 USPATFULL  
 TITLE: Novel human membrane protein and polynucleotides  
 encoding the same  
 INVENTOR(S): Walke, D. Wade, Spring, TX, United States  
 Wilganowski, Nathaniel L., Houston, TX, United States  
 Turner, C. Alexander, JR., The Woodlands, TX, United  
 States  
 Friedrich, Glenn, Houston, TX, United States  
 Abuin, Alejandro, The Woodlands, TX, United States  
 Zambrowicz, Brian, The Woodlands, TX, United States  
 Sands, Arthur T., The Woodlands, TX, United States

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2001034438	A1	20011025	<--
APPLICATION INFO.:	US 2001-755017	A1	20010105	(9)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2000-175764P	20000112 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	LEXICON GENETICS INCORPORATED, 4000 RESEARCH FOREST DRIVE, THE WOODLANDS, TX, 77381	
NUMBER OF CLAIMS:	4	
EXEMPLARY CLAIM:	1	
LINE COUNT:	2038	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The nucleotide and amino acid sequences of a novel human G  
 protein-coupled receptor (NGPCR) is disclosed. The NGPCR is somewhat  
 similar to human latrophilin, lectomedin, and serpentine, proteins,  
 among others.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.